Subject(s)
Hypertension, Pulmonary/complications , Macular Edema/etiology , Retinal Detachment/diagnosis , Retinal Detachment/etiology , Amlodipine/adverse effects , Amlodipine/therapeutic use , Antihypertensive Agents/adverse effects , Antihypertensive Agents/therapeutic use , Diagnosis, Differential , Drug Therapy, Combination , Female , Humans , Hypertension, Pulmonary/drug therapy , Macular Edema/diagnosis , Metoprolol/adverse effects , Metoprolol/therapeutic use , Middle Aged , Phosphodiesterase 5 Inhibitors/adverse effects , Phosphodiesterase 5 Inhibitors/therapeutic use , Sildenafil Citrate/adverse effects , Sildenafil Citrate/therapeutic use , Vision Disorders/etiologyABSTRACT
UNLABELLED: Aim of the study was to estimate the efficacy of 6-alpha-methylprednisolone injection into involved extraocular muscles in eyes with motility disturbances caused by endocrine ophthalmopathy. MATERIAL AND METHODS: For further evaluation we qualified 4 patients, 1 female and 3 males, aged: 60, 43, 42 and 64 years, with clinical activity score equal 4, with duration of Graves' ophthalmopathy of mean 2.1 years (0.16 - 5.5). Included were patients with movement restrictions in vertical plane and echographic findings of isolated extraocular muscle involvement (inferior rectus). Each of the patients received 20 mg 6-alpha-methylprednisolone into the muscle belly of inferior rectus, in one case injection was done in both eyes. RESULTS: In all cases we were able to archive lessening of the intraocular pressure in secondary position, with slight improvement in ocular motility and bigger range of duction free of diplopia. CONCLUSIONS: Visual function improvement found by the patients is the best evidence for application of 6-alpha-methylprednisolone into the extraocular muscles of patients with motility disturbances secondary to endocrine ophthalmopathy.
